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Conventional treatments of osteoarthritis (OA) reduce pain and the inflammatory response but do not repair the damaged
cartilage. Xenogeneic peripheral blood-derived equine chondrogenically induced mesenchymal stem cells (ciMSC) could thus
provide an interesting alternative. Six client-owned dogs with confirmed elbow OA were subjected to a baseline orthopedic
examination, pressure plate analysis, general clinical examination, hematological analysis, synovial fluid sampling, and
radiographic examination, and their owners completed two surveys. After all examinations, a 0.9% saline solution (placebo
control product = CP) was administered intra-articularly. After 6 weeks, all examinations were repeated, owners again
completed two surveys, and equine ciMSCs were administered in the same joint. After another 6 weeks, dogs were returned for
a final follow-up. No serious adverse events or suspected adverse drug reactions were present during this study. No significant
differences in blood analysis were noted between the CP and ciMSC treatment. Two adverse events were observed, both in the
same dog, one after CP treatment and one after ciMSC treatment. The owner surveys revealed significantly less pain and
lameness after ciMSC treatment compared to after CP treatment. There was no significant difference in the orthopedic
examination parameters, the radiographic examination, synovial fluid sampling, and pressure plate analysis between CP
treatment and ciMSC treatment. A single intra-articular administration of equine ciMSCs proved to be a well-tolerated
treatment, which reduced lameness and pain according to the owner’s evaluations compared to a placebo treatment.
1. Introduction
Conventional pharmacological treatments of osteoarthritis
(OA) consist of non-steroidal anti-inflammatory drugs
(NSAIDs) and/or corticoids. These pharmaceuticals reduce
pain and the inflammatory response, but do not repair the
inflicted damage to the cartilage [1–3]. Therefore, adult
mesenchymal stem cells (MSCs) are an interesting alternative
to treat OA, since they can differentiate into different cell
lineages, promote the migration of endogenous repair cells,
and have an immunomodulatory and immunosuppressive
effect [1, 2, 4]. In humans, several studies have been per-
formed using autologous MSCs to treat OA, with overall pos-
itive results on safety and efficacy [5]. Similarly in dogs,
several studies describe promising results using autologous
adipose-derived MSCs [6–10]. However, for treatment pur-
poses, allogeneic or xenogeneic MSCs are a more appealing
option, since these preclude the need of harvesting tissues
of each individual patient and eliminate the prolonged period
needed for the production of the “ready-to-treat” end prod-
uct [2, 5, 11, 12]. Moreover, the quantity and quality of MSCs
decline with the increasing age of the donor [1, 13], which
poses a problem as OA becomes more prevalent with aging.
Thus, allogeneic or xenogeneic transplantation of MSCs
could address this problem, since this allows for a stringent
selection of healthy and high qualitative donors. Xenogeneic
MSCs are interesting in particular, as tissue harvesting from
readily available healthy donor animals could provide a very
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cost-effective solution to produce MSCs for human applica-
tions. Especially, as the MSC source is minimally invasive
such as peripheral blood, so harvesting can be performed
repeatedly with minimal donor site morbidities and little dis-
comfort for the animal. Additionally, for dogs specifically,
their MSCs have a low potential for commercial applications,
since canine MSCs display a reduced culture capacity and
early senescence compared to human and equine MSCs
[14–16]. Another advantage of using xenogeneic MSCs is
the absence of the risk of transferring highly virulent
species-specific pathogens associated with transfusing blood
or plasma-derived products (hepatitis B in humans, canine
distemper virus in dogs, etc.) [17, 18].
The feasibility and safety of the use of xenogeneic MSC
for treating various diseases have been increasingly investi-
gated [12, 19, 20]. Since canine models are regularly used
for human OA [21], valuable information on xenotransplan-
tation of MSCs can be obtained from animal studies using
dogs. However, to date, the use of peripheral blood-derived
MSCs to treat OA in dogs has not been tested. Moreover,
the environment in a degenerated joint might not provide
the correct stimulus for MSC differentiation and signaling
or, alternatively, may even negatively influence their func-
tionality. Therefore, a chondrogenic induction of MSCs
before treatment may improve the clinical outcome. Based
on recent studies, the intra-articular administration of
peripheral blood-derived allogeneic chondrogenic induced
MSCs (ciMSCs) in horses effectively reduces lameness and
joint effusion, yields some chondroprotective effects, and
provides a safe treatment for mild to moderate joint inflam-
mation [22–24]. Therefore, a study was performed to evalu-
ate the feasibility of a single intra-articular administration
of equine peripheral blood-derived ciMSCs as a treatment
for OA in dogs. It was hypothesized that xenogeneic admin-
istration of ciMSCs would provide a safe treatment and
would effectively reduce lameness. The results of this study
will also provide some preliminary information on the feasi-
bility of this treatment for the application in humans.
2. Materials and Methods
2.1. Study Design and Eligibility Criteria. This study was a
prospective placebo-controlled clinical study and was
approved by the local ethics committee of Global Stem Cell
Technology (approval number EC_2016_002; permit number
LA1700607). Additionally, the study was conducted accord-
ing to applicable European and national regulatory require-
ments and in compliance with Directive 2010/63/EU. An
informed consent was obtained from all the owners. All
patients with suspected OA of the humeroradial joint admit-
ted to the clinical study site were screened for eligibility in this
study. Dogs were enrolled in this study if they presented stable
pain and lameness associated with unilateral or bilateral OA
of the humeroradial joint lasting for over 1 month. The OA
had to be confirmed based on a clinical examination, includ-
ing a lameness examination, and a radiographic examination
according to guidelines of the international elbow group [25].
The animals had to weigh ≥ 10 kg and had to be older than 6
months. Animals were excluded from the study if they showed
signs of a systemic disease (based on a general clinical exami-
nation and general hematological analysis) or if they pre-
sented signs of a disease(s) that could affect the gait (e.g.,
neurological disorder) prior to enrollment. Pregnant bitches
were not allowed in the study. NSAIDs were allowed during
the study period if dogs started treatment at least 7 days prior
to day 0 and remained on the treatment on the same dose dur-
ing the entire study period of 12 weeks. Corticosteroids were
not allowed during the study period or within 60 days before
the start of the study. Any intra-articular treatments or the
administration of antibiotics were not allowed during the
study period.
2.2. Isolation and Chondrogenic Induction of Mesenchymal
Stem Cells. The equine chondrogenic induced mesenchymal
stem cells (ciMSCs) were produced according to GMP guide-
lines in a GMP-certified site (nr. BE/GMP/2016/069) as
described earlier [24]. Briefly, MSCs were isolated from the
peripheral blood collected from the vena jugularis from a sin-
gle donor horse using a proprietary method. The blood col-
lection of the donor horse was approved by the local ethics
committee of Global Stem Cell Technology NV (EC_2012_
001 and 2016_003), and the blood was tested for several
equine pathogens at Böse laboratory (Harsum, Germany).
Isolated MSCs were cultured until passage 5, after which they
were characterized as described previously (i.e., determina-
tion of cell viability, morphology, presence or absence of cell
surface markers, trilineage differentiation, and population
doubling times) and frozen [14]. Cells were subsequently
thawed, cultured, and chondrogenically induced from pas-
sage 9 to passage 10, using a proprietary method and propri-
etary cell culture medium containing cartilage-inducing
growth factors. The cells were characterized by evaluating
the gene expression of a chondrogenic marker (cartilage olig-
omeric matrix protein (COMP)), the presence of cell surface
markers (MHC II, CD44, and CD90), the total cell number,
population doubling time, viability, and sterility. After chon-
drogenic induction, ciMSCs were detached, resuspended in
1mL of Dulbecco’s modified Eagle medium low glucose with
10% dimethyl sulfoxide (DMSO, Sigma-Aldrich, Overijse,
Belgium) at a concentration of 2 × 106 cells per mL and fro-
zen at −80°C in cryovials until clinical application.
2.3. Treatment Allocation. At day 0, all dogs enrolled in this
study were first treated intra-articularly in their most severely
affected humeroradial joint with a placebo control product
(CP) (0.5mL of 0.9% saline solution). Six weeks later (week
6), after the dogs underwent all examinations and the owner
surveys were collected, the ciMSCs were thawed and 0.5mL
was administered intra-articularly (1 × 106 cells) in the same
humeroradial joint. Six weeks after ciMSC treatment (week
12 = study end), dogs were brought back for a final follow-
up, by which they underwent all examinations and the owners
completed the owner surveys. With both intra-articular
administrations, the dogs received cimicoxib (2mg/kg, tablet)
PO once a day with the first 7 days as a concomitant treatment
to minimize inflammation after the injection. In the first 10
days after treatment, the dogs were also subjected to home
confinement and leash walking.
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2.4. General Clinical Examination and Hematological
Analysis. At day 0, week 6, and week 12, all dogs underwent
a general clinical examination, consisting out of an evalua-
tion of rectal temperature, heart rate, respiratory rate, muco-
sal membrane color, capillary refill time, body condition
score, hydration, mentation, and behavior of the dog. Addi-
tionally, the blood was collected for a hematological and bio-
chemical analysis (Table 1). Owners were asked to monitor
their dog daily for (serious) adverse events and suspected
drug reactions and, in case of the presence of an adverse
event, to return for a clinical examination of the dog.
2.5. Pressure Plate Analysis. Before treatment at the start of
the study, at week 6 before ciMSC administration and at week
12, all dogs underwent an objective lameness examination
using an instrumented treadmill with an integrated pressure
plate (GAIT4Dog treadmill, GAIT4Dog, Franklin, New
Jersey, USA). Dogs were walked on the treadmill with a
velocity between 1.5 and 4.5 km/h depending on the dog’s
size and temperament. The following parameters were
recorded using the dedicated GAIT4Dog software program:
stance time (the time elapsed between the first contact and
the last contact of one identified paw in sec), stride length
(the distance in cm between the heel points of two consecu-
tive paw prints of the same paw), reach (the distance in cm
from the heel center of the hind paw to the heel center of
the previous forepaw on the same side), stance % (the per-
centage of stance time compared to stride time), pressure %
(the integrated pressure over time for a paw expressed as a
percent of the overall integrated pressure over time), and
the GAIT4Dog lameness score (GLS). With the GLS system,
number 100 presents a normal pressure distribution over the
paw of interest and a higher or lower number represents a
reduced or increased loading of that paw, respectively.
2.6. Orthopedic Examination. At day 0, week 6, and 12, an
observational gait analysis was performed using the score
system as depicted in Table 2. Additionally, the range of
motion of the injected humeroradial joint was determined
using a goniometer and a score system (Table 2). Articular
pain, joint effusion, and the impact of the lameness on the
clinical condition were also scored as presented in Table 2.
2.7. Synovial Fluid Sampling. At baseline (day 0), at week 6
(before ciMSC injection), and at week 12, synovial fluid was
collected, which was checked for hemarthrosis and scored
for viscosity (Table 2).
2.8. Radiographic Examination. At day 0, week 6, and week
12, radiographs of both elbow joints were taken according
to International Elbow Working Group guidelines [25].
Briefly, two mediolateral projections and one craniocaudal
projection of each humeroradial joint were taken. One med-
iolateral projection was taken with the humeroradial joint in
flexion (30-40 degrees) and one with the humeroradial joint
in neutral position (100–120 degrees). The craniocaudal pro-
jection was taken with a 10-degree pronated rotation. The
joints were scored for the presence of OA using the following
score system: 0 = normal elbow joint, no evidence of incon-
gruency, sclerosis, or arthrosis (no OA); 1 = presence of
osteophytes < 2mm high, sclerosis of the base of the
coronoid process—trabecular pattern still visible (mild
OA); 2 = presence of osteophytes of 2-5mm high, obvious
sclerosis (no trabecular pattern) of the base of the coronoid
processes (moderate OA); and 3 = osteophytes of over
5mm found anywhere in the joint (severe OA). Additionally,
the presence of the following primary lesions was noted:
malformed or fragmented medial coronoid process (FCP),
ununited anconeal process (UAP), osteochondrosis of medial
aspect of humeral condyle, incongruity of articular surface
(INC) (step of >5mm between radius and ulna), and calcifi-
cation in the soft tissue.
2.9. Owner Surveys. At day 0, week 6, and week 12, owners
were asked to complete two owner surveys. One survey was
created based on the study of Hudson et al. [26] and con-
sisted out of 11 questions using a visual analogue scale of
10 cm. One question gauged the owners’ overall evaluation
of the dog’s pain and life quality. Three questions concerned
the dog’s mood, three concerned the dog’s amount of activity,
two concerned the dog’s stiffness, and two concerned the
dog’s pain. The left side of the visual analogue scale
Table 1: Parameters determined during the hematological and
biochemical analysis of blood samples.
Parameter Unit
Normal reference
range
Hematology
Erythrocytes /L 5.65-8 87 × 1012
Hemoglobin g/dL 13.1-20.5
Hematocrit % 37.3-61.7
MCV fL 61.6-73.5
MHV pg 21.2-25.9
MCHC g/dL 32.0-37.9
Leucocytes /L 5.05-16 76 × 109
Differential blood picture—absolute
Neutrophils /L 2.95-11 64 × 109
Eosinophils /L 0.06-1 23 × 109
Basophils /L 0.00-0 10 × 109
Lymphocytes /L 1.05-5 1 × 109
Monocytes /L 0.16-1 12 × 109
Renal function
Creatinine mmol/L 3.89-7.95
Urea mmol/L 2.5-9.6
Protein metabolism
Total protein g/L 52-82
Liver and bile
Total bilirubin μmol/L 0-15
Gamma glutamyltransferase (GGT) U/L 0-11
Alkaline phosphatase U/L 23-212
Lactate dehydrogenase (LDH) U/L 40-400
Heart and muscle
Creatine kinase (CK) U/L 10-200
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corresponded with the “worst-case” scenario (very bad mood
of the dog, very stiff, very lame, etc.), and the right side of the
visual analogue scale corresponded with the “best case” sce-
nario (very good mood, no stiffness, not lame, etc.). The sec-
ond survey consisted of the validated canine brief pain
inventory (CBPI) [27]. This survey consists of two parts.
One part gauges the owner’s evaluation of the dog’s pain at
its worst, at its least, on average, and right now on a scale
from 0 to 10, with 0 representing “no pain” and 10 represent-
ing “extreme pain.” Themean of these 4 scores was calculated
to obtain the pain severity score (PSS). The second part of the
survey evaluates the interference of the dog’s pain with its
general activity, its enjoyment of life, and its ability to rise,
to walk, to run, and to climb stairs again on a scale of 0 to
10 with 0 being “no interference” and 10 being “completely
interferes.” The mean of these 6 scores was calculated to
obtain the pain interference score (PIS). The CBPI also
includes a separate question on the owner’s assessment of
the quality of life of his/her dog on a 5-point scale from
“poor” to “excellent.”
2.10. Statistical Analysis. All statistical analyses were per-
formed using IBM SPSS Statistics for Windows, version
25.0. Normal distributed continuous data was analyzed using
paired sample t-tests for comparing the two treatment
groups. Normal distribution of the differences of continuous
data was checked using Kolmogorov-Smirnov tests and Q-Q
plots. Not normally distributed data or ordinal data was ana-
lyzed using related sample Wilcoxon signed-rank tests.
Binary data was analyzed using related sample McNemar
tests. A P < 0 05 was considered to be statistically significant.
3. Results
3.1. Isolation and Chondrogenic Induction of Mesenchymal
Stem Cells. The cells at passage 5 displayed all properties of
MSCs. They were able to adhere to plastic, a successful trili-
neage differentiation was achieved, and the cells were positive
for CD29 (100%), CD44 (100%), and CD90 (100%) and neg-
ative for CD45 (1%) and MHC II (0%). The average popula-
tion doubling time (PDT) over 10 passages was 1.4. Passage
Table 2: Explanatory overview of the score systems used for the orthopedic examination and synovial fluid sampling.
Parameter Score Definition
Lameness assessment
1 Stands, walks, and trots normally
2 Stands normally, slightly painful gait when trotting
3 Stands normally, slightly painful gait when walking
4 Stands normally, evident painful gait when walking
5 Stands abnormally, evident painful gait when walking
Range of motion
1 No limitation of movement or crepitus
2 10 to 20 percent decrease in range of motion, no crepitus
3 10 to 20 percent decrease in range of motion with crepitus
4 20 to 50 percent decrease in range of motion
5 More than 50 percent decrease in range of motion
Articular pain
1 None
2 Mild signs (dog turns head in recognition)
3 Moderate signs (dog pulls limb away)
4 Severe signs (dog vocalizes or becomes aggressive)
5 Dog will not allow palpation
Joint effusion
1 None
2 Mild signs (only at site of injection)
3 Moderate signs (mild swelling of entire joint)
4 Severe signs (severe swelling of entire joint)
5 Extreme (periarticular swelling)
Impact on clinical condition
1 Not affected
2 Mildly affected
3 Moderately affected
4 Severely affected
5 Very severely affected
Synovial fluid viscosity
1 Watery, no string
2 Tacky, string < 0 5 cm
3 String 0.5-4 cm
4 String > 4 cm
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10 ciMSCs displayed a successful chondrogenic induction
(4.4-fold COMP expression), 96% viability, and the presence
of an MSC immunophenotype (87% CD44, 98% CD90, and
0% MHC II).
3.2. Animals. A total of 6 client-owned dogs were enrolled in
this study: 3 intact males and 3 spayed females, aged 5 to 10
years, with a body weight of 18 to 52.5 kg. The dogs belonged
to the following breeds: Labrador Retriever (n = 2), German
Shepherd (n = 1), American Staffordshire Bull Terrier (n = 1),
Rhodesian Ridgeback (n = 1), and Dutch Partridge (n = 1).
3.3. General Clinical Examination and Blood Analysis. No
serious adverse events or suspected adverse drug reactions
were noted during the entire study period. One dog por-
trayed occasional nonproductive vomiting during the entire
study period, starting 6 days after the CP administration.
The dog was treated with 10 days of 40mg of omeprazole
(Omeprazole Sandoz, Sandoz, Vilvoorde, Belgium) starting
three days before ciMSC administration. The same dog also
portrayed 4 days of diarrhea and vomiting 1 week after the
ciMSC administration, when the omeprazole treatment was
ended. For this event, the dog received a complementary feed
for 5 days, consisting of electrolytes, methylsulfonylmethane,
and cranberry (Protectdiar forte, tablets, Ecuphar, Oost-
kamp, Belgium) and probiotics for 7 days (Fortiflora, Purina,
Brussel, Belgium). Both adverse events were presumably due
to the concomitant NSAID administration after the intra-
articular treatment administration of study products.
None of the parameters measured on the clinical exami-
nation was significantly different between the CP evaluation
point (week 6) and the ciMSC evaluation point (week 12).
There were also no significant differences in parameters mea-
sured during the hematological and biochemical analysis of
the blood between the two treatments.
3.4. Pressure Plate Analysis. There was no significant dif-
ference in any of the parameters measured with the pres-
sure plate analysis between CP treatment and ciMSC
treatment (Figure 1).
3.5. Orthopedic Examination. Despite the observed improve-
ment in lameness scores after the ciMSC treatment when the
data was examined descriptively (Figure 2(a)), the difference
between the treatment groups was not significantly different
(P = 0 083). Additionally, when the data was examined
descriptively, joint effusion seemed to increase after both
CP and ciMSC administrations (Figure 2(b)). However, no
significant difference was seen between the treatment groups
(P = 0 564). The other parameters, i.e., the range of motion in
degrees and scores, articular pain, and impact on clinical
condition, were also not significantly different between the
treatment groups.
3.6. Synovial Fluid Sampling. Hemarthrosis was present in 2
animals at baseline, in 4 animals after CP treatment (week
6 before ciMSC administration), and in 2 animals after
ciMSC treatment (week 12). The differences between the
CP and MSC treatment were not statistically significant.
The viscosity of synovial fluid was also not significantly dif-
ferent between the treatment groups.
3.7. Radiographic Examination.At baseline, 1 dog was scored
with mild OA based on the radiographic examinations, 3
dogs were scored with moderate OA, and 2 dogs were scored
with severe OA. After CP treatment (week 6), 1 dog shifted
from moderate OA to severe OA. After ciMSC treatment
(week 12), the distribution of the dogs across the score cate-
gories remained the same as after the CP treatment.
3.8. Owner Surveys. Three questions of the owner survey
based on the study of Hudson et al. [26] were graded signif-
icantly different between CP treatment and ciMSC treatment
(Figure 3). The owners scored the attitude of their dog during
the preceding month/evaluation period significantly better
after ciMSC treatment compared to after CP treatment
(P = 0 016). The owners also evaluated their dog significantly
less lame while walking after ciMSC treatment compared to
after CP treatment (P = 0 045). Additionally, the owners
indicated their dog displayed significantly less pain when
turning suddenly while walking after ciMSC treatment com-
pared to after CP treatment (P = 0 025).
For the canine brief pain inventory survey, several ques-
tions were scored significantly different after CP treatment
than after ciMSC treatment. The owners scored the pain of
their dogs at its least, at its worst, on average, and as it was
on the moment of the survey significantly less after ciMSC
treatment compared to CP treatment (P = 0 04, P = 0 008,
P = 0 007, and P = 0 048, respectively) (Figure 4). Addi-
tionally, the owners found that the pain interfered signifi-
cantly less with the ability of the dog to walk and run after
ciMSC treatment compared to after CP treatment
(P = 0 034 and P = 0 049, respectively). The PSS was signif-
icantly lower after ciMSC treatment compared to after CP
treatment (P = 0 013) (Figure 5). The PIS was also lower
after ciMSC treatment compared to after CP treatment,
albeit not statistically significant (P = 0 087) (Figure 5).
4. Discussion
This study was the first to investigate the feasibility of periph-
eral blood-derived equine ciMSCs as a treatment for OA in
dogs. In line with our hypothesis, equine ciMSC proved to
be a well-tolerated treatment for OA in dogs. No suspected
adverse drug reactions or serious adverse events were noted.
There was however an increase in joint effusion after both CP
and ciMSC treatments when the data was examined descrip-
tively. This increase in joint effusion was not significantly
different between the treatment groups, and joint swelling
has been a reported phenomenon after intra-articular injec-
tions in general [28]. Moreover, the effusion was noted 6
weeks after intra-articular administration of the treatments,
suggesting the effusion could have another cause, such as
an increased activity of the dog. There were two reported
adverse events in this study, both presented by the same
dog: one after CP administration and one after ciMSC
administration. Both adverse events were judged by the
investigating veterinarian to be unrelated to the study
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Figure 1: Box plot representation of (a) the stance time, (b) the stride length, (c) the pressure %, (d) the GAIT4Dog lameness score, (e) the
reach, and (f) the stance % measured with the pressure plate analysis at baseline (day 0), after placebo control product (CP) administration
(week 6) and after xenogeneic chondrogenic induced mesenchymal stem cell (ciMSC) administration (week 12). No significant differences
were noted in any of the parameters between CP treatment and ciMSC treatment.
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treatments. Furthermore, the owners of this dog reported
previous similar problems outside the study due to long-
term use of NSAIDs.
The second part of our hypothesis was partly fulfilled.
The administration of ciMSCs significantly reduced lame-
ness, albeit only based on the owner surveys. When the data
of the veterinary examinations were examined descriptively,
a decrease in lameness was seen after both treatment admin-
istrations, with a larger decrease after ciMSC administration.
However, this decrease was not significantly different. Since
the P value was low (0.083), it is possible that the statistical
significance would have been reached by including a larger
number of dogs in the study. However, it proved to be very
difficult to motivate owners to participate in a placebo-
controlled study with a cell-based product still in the experi-
mental phase. Moreover, the xenogeneic factor of the study
raised additional concerns with the owners about safety and
stem cell rejection. Therefore, all dogs enrolled in this study
were older dogs who did not respond to conventional treat-
ments, of which the owners considered the ciMSCs as a “last
resort treatment.” Since most of these dogs presented moder-
ate to severe OA, profound damage was already present in
the joint. Therefore, to observe amelioration in these animals,
the effect of the ciMSCs had to be outspoken.
The objective lameness assessment did not reveal any sig-
nificant difference between the treatment groups. However, it
was proved to be difficult to have the dogs walk naturally on
the treadmill. Most dogs had the tendency to start pulling the
leash or to walk towards the side of the belt to try to lean
against the side fences, despite a 10-minute acclimatization
period. This resulted in the pressure plate indicating all dogs
were lame in both or one hind limb, although they all had a
clear history of humeroradial OA. Additionally, one dog
was omitted from the objective lameness assessment because
of its nervous temperament. Therefore, data of the pressure
plate analysis in this study should be interpreted carefully.
The safety in this study was assessed by means of clinical
examination and blood analysis. No increase in white blood
cell counts, its individual subsets, or globulins after either
treatmentwas noted.However, to get amore profound insight
in the safetyof ciMSCsasa therapy forOAdogsandona longer
term for humans, functional immunological assays such as
mixed lymphocyte reactions or xenoantibody determination
should be performed. After all, MHC-mismatched MSCs
have been shown to induce alloantibodies in horses [29, 30].
Additionally, xenogeneic MSC administration in horses has
been reported to induce an increase of CD4+ cells as deter-
mined with mixed lymphocyte reactions [31]. Therefore, it
would be interesting to investigate if similar results are seen
after the administration of equine ciMSC in dogs.
Although xenogeneic use of MSCs has been described,
most studies use humane or porcine MSCs in animal
models [12, 19, 32, 33]. Of these studies, Tsai et al. [33]
reported on the intra-articular administration of porcine
adipose-derived MSCs. Similar to the present study, they
found that the owners evaluated an improvement in the dogs’
pain and their capacity to perform activities. Additionally,
they found no radiographic changes before or after treatment
and no allergic reactions. Joint effusion as such was not deter-
mined in this study. Tsai et al. [33] also found an improve-
ment in an overall orthopedic score and the peak vertical
force and vertical impulse when comparing after treatment
values with baseline values. However, they did not include a
placebo control and the study consisted of only three cases.
Additionally, all statistical analyses were performed per case.
Thus, a parameter of the orthopedic examination, a question
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Figure 2: Distribution of the number of dogs over the different (a) lameness score and (b) joint effusion score categories at baseline (day 0),
after placebo control product (CP) administration (week 6) and after xenogeneic chondrogenic induced mesenchymal stem cell (ciMSC)
administration (week 12).
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of the owner questionnaire, or one run of the force plate analy-
sis was considered as an experimental unit. Since an experi-
mental unit should normally be a subject/entity which can
receive a treatment independently of the other units, the con-
clusions in the studyofTsai et al. [33] are to be interpretedwith
care. Amore recent study described the use of equineMSCs in
an OA mouse model [34]. They found a chondroprotective
effect of the equine MSCs when compared to no treatment.
Additionally, they reported the ability of equine MSCs to
decrease murine splenocyte proliferation in vitro, suggesting
an immunomodulatory effect of the stem cells. The present
study focused on the clinical effects of xenogeneic administra-
tion of equine ciMSCs in client-owned dogs with promising
results. However, this precluded the possibility to perform a
macroscopic and histologic examination of the joint and to
assess possible cartilage regeneration or a chondroprotective
effect. Therefore, a follow-up study performed on experimen-
tal animals using anOAmodel is recommended to investigate
thehistological effectsof theequineciMSCsandperformanin-
depth examination if the cells induce an immune response.
The present study has its limitations; it was not blinded
and performed on a rather limited number of dogs. Addition-
ally, a full cross-over design (placebo administration followed
by ciMSCs and a washout period, followed by a new ciMSC
administration and placebo administration) was not possible
in the same dogs, as it is not known how long the washout
period is for stem cells, if there is one at all. The inclusion of
more dogs, as mentioned earlier, was not possible, because
of the great reluctant of the owners to participate in a
placebo-controlled study containing a stem cell product still
in the experimental phase. Therefore, this study has to be con-
sidered a pilot study which investigated the feasibility of
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Figure 3: Mean scores (±standard error of the mean) of three questions of the owner survey based on the study of Hudson et al. [26] at
baseline (day 0), after placebo control product (CP) administration (week 6) and after xenogeneic chondrogenic induced mesenchymal
stem cell (ciMSC) administration (week 12). The asterisk (∗) indicates a significant difference in mean scores between the two treatment
groups (P < 0 05).
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ciMSC as a treatment for naturally occurring OA in dogs and
in humans. Based on this study, the treatment proved to be
feasible, but further follow-up studies using experimental
dogs are necessary. Further studies are preferably random-
ized, double blinded, and placebo controlled and could also
assess the added value of repeated injections and their safety.
5. Conclusion
The single intra-articular administration of equine ciMSCs to
treat naturally occurring OA in dogs proved to be a well-
tolerated treatment, which reduced lameness and pain
according to the owner’s evaluations compared to a placebo
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Figure 4: Mean scores (±standard error of the mean) of the questions on pain of the canine brief pain inventory at baseline (day 0), after
placebo control product (CP) administration (week 6) and after xenogeneic chondrogenic induced mesenchymal stem cell (ciMSC)
administration (week 12). The asterisk (∗) indicates a significant difference in mean scores between the two treatment groups (P < 0 05).
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Figure 5: Mean scores (±standard error of the mean) of the pain severity score (PSS) and pain interference score (PIS) at baseline (day 0),
after placebo control product (CP) administration (week 6) and after xenogeneic chondrogenic induced mesenchymal stem cell (ciMSC)
administration (week 12). The asterisk (∗) indicates a significant difference in mean scores between the two treatment groups (P < 0 05).
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treatment. Therefore, this study provides the base for further
research investigating the mechanisms of action of equine
ciMSCs on OA and initiating the development of a new treat-
ment protocol for OA.
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